Structure-Based Design of Type II Inhibitors Applied
to Maternal Embryonic Leucine Zipper Kinase |
| |
| Authors: | Christopher N. Johnson,Christophe Adelinet,Valerio Berdini,Lijs Beke,Pascal Bonnet,Dirk Brehmer,Frederick Calo,Joseph E. Coyle,Phillip J. Day,Martyn Frederickson,Eddy J. E. Freyne,Ron A. H. J. Gilissen,Christopher C. F. Hamlett,Steven Howard,Lieven Meerpoel,Laurence Mevellec,Rachel McMenamin,Elisabeth Pasquier,Sahil Patel,David
C. Rees,Joannes T. M. Linders |
| |
| Affiliation: | †Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom;‡Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse 2340, Belgium;§Janssen Research and Development, A Divisionof Janssen-Cilag , BP615-Chaussée du Vexin, 27106 Val-de-Reuil, France |
| |
| Abstract: | ![]()
| |
| Keywords: | Maternalembryonic leucine zipper kinase fragment-based drug design structure-based optimization |
|
|
